Valuation: Orion Oyj

Market Cap 11.48B 13.18B 10.83B 9.84B 18.43B 1,264B 18.5B 130B 50.06B 643B 49.48B 48.38B 2,069B P/E 2026 *
20.3x
P/E 2027 * 17.2x
Enterprise Value 11.39B 13.07B 10.75B 9.76B 18.29B 1,254B 18.35B 128B 49.67B 638B 49.1B 48B 2,053B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 4.69x
Free-Float
90.5%
Yield 2026 *
2.39%
Yield 2027 * 2.66%
1 week 63.4
Extreme 63.4
63.4
1 month 63.4
Extreme 63.4
63.4
3 years 52.69
Extreme 52.69
63.55
5 years 36
Extreme 36
63.55
10 years 24.85
Extreme 24.85
63.55
Manager TitleAgeSince
Chief Executive Officer 59 31/10/2022
Director of Finance/CFO 50 30/04/2024
Chief Operating Officer 46 31/12/2021
Director TitleAgeSince
Director/Board Member 63 21/03/2017
Director/Board Member 65 21/03/2017
Director/Board Member 66 05/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%+18.50% 13.16B
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average +0.04%+3.26%+22.72%+42.67% 400.19B
Weighted average by Cap. -0.04%+3.09%+34.72%+61.44%

Financials

2026 *2027 *
Net sales 2.1B 2.41B 1.98B 1.8B 3.37B 231B 3.38B 23.67B 9.15B 118B 9.04B 8.84B 378B 2.37B 2.73B 2.24B 2.04B 3.81B 261B 3.83B 26.78B 10.35B 133B 10.23B 10.01B 428B
Net income 566M 650M 534M 485M 909M 62.32B 912M 6.39B 2.47B 31.71B 2.44B 2.39B 102B 668M 767M 630M 573M 1.07B 73.55B 1.08B 7.54B 2.91B 37.42B 2.88B 2.82B 120B
Net Debt -89.76M -103M -84.73M -76.96M -144M -9.88B -145M -1.01B -392M -5.03B -387M -378M -16.18B -333M -382M -314M -285M -535M -36.66B -537M -3.76B -1.45B -18.66B -1.44B -1.4B -60.02B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
-
Date Price Change
18/09/26 €63.40 0.00%
17/09/26 €63.40 0.00%
16/09/26 €63.40 0.00%
15/09/26 €63.40 0.00%
14/09/26 €63.40 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
81.50EUR
Average target price
76.67EUR
Spread / Average Target
-5.93%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!